Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease

Ladan Zand, Vicente E. Torres, Timothy S. Larson, Bernard F. King, Sanjeev Sethi, Eric J. Bergstralh, Andrea Angioi, Fernando C. Fervenza

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Background To determine the effect of statins on renal hemodynamics in normal volunteers and those with autosomal dominant polycystic kidney disease either with mild or moderate renal dysfunction. Methods Thirty-two study subjects were enrolled in this study: 11 normal volunteers, 11 study subjects with autosomal dominant polycystic kidney disease (ADPKD) and mild kidney disease and 10 study subjects with ADPKD and moderate kidney disease. Subjects in each group received simvastatin 40 mg once daily for a period of 4 weeks. Renal blood flow was measured based on para-amino-hippurate (PAH) clearance and with the use of a magnetic resonance (MR) scanner at the beginning and following 4 weeks of therapy with statins. Results At the end of the study, except for the lipid profile, which was significantly lower in all groups, other laboratory results showed no change. Four weeks of therapy with simvastatin resulted in no change in serum creatinine, 24-h urinary protein, sodium, iothalamate clearance, PAH clearance or renal blood flow as measured by MRI or based on PAH clearance. Conclusions Four weeks of therapy with simvastatin did not change renal blood flow in the study subjects with ADPKD with mild-to-moderate renal dysfunction or in healthy volunteers.

Original languageEnglish (US)
Pages (from-to)1290-1295
Number of pages6
JournalNephrology Dialysis Transplantation
Volume31
Issue number8
DOIs
StatePublished - Aug 1 2016
Externally publishedYes

    Fingerprint

Keywords

  • ADPKD
  • HMG-CoA reductase inhibitor
  • Renal blood flow
  • Statins

Cite this

Zand, L., Torres, V. E., Larson, T. S., King, B. F., Sethi, S., Bergstralh, E. J., Angioi, A., & Fervenza, F. C. (2016). Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 31(8), 1290-1295. https://doi.org/10.1093/ndt/gfv394